Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
February 07, 2025 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
February 05, 2025 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
February 04, 2025 16:31 ET
|
Annovis Bio, Inc.
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
February 03, 2025 06:22 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio, Inc. Announces Proposed Public Offering
January 31, 2025 20:14 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
January 14, 2025 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for...
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
January 07, 2025 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis to Host Year-End Investor Webcast on December 11, 2024
November 25, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased...
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
November 12, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
November 11, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...